Kostas Biliouris
Stock Analyst at BMO Capital
(0.74)
# 3,839
Out of 4,876 analysts
57
Total ratings
25%
Success rate
-22.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $300 → $360 | $321.32 | +12.04% | 5 | Jun 24, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | $120 → $70 | $17.38 | +302.76% | 5 | Jun 16, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $2.57 | +211.28% | 2 | May 28, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $72 | $29.68 | +142.59% | 1 | Mar 12, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $9.88 | +406.07% | 1 | Mar 12, 2025 | |
| SLN Silence Therapeutics | Maintains: Outperform | $67 → $25 | $5.91 | +323.01% | 2 | Mar 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Market Perform | $60 → $45 | $39.80 | +13.07% | 2 | Feb 20, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $70 → $50 | $9.75 | +412.82% | 6 | Jan 10, 2025 | |
| DTIL Precision BioSciences | Upgrades: Outperform | $34 | $4.35 | +681.61% | 3 | Jan 10, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $20 → $35 | $12.97 | +169.85% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $17 | $1.59 | +969.18% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $40 | $4.03 | +892.56% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $35.80 | +151.40% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $12.21 | +882.80% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $17.21 | +231.20% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $44.99 | -17.76% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $54.95 | +81.98% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $2.51 | +656.97% | 1 | Oct 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $62 | $11.29 | +449.40% | 2 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $47.47 | +106.45% | 1 | Jun 17, 2022 |
Alnylam Pharmaceuticals
Jun 24, 2025
Maintains: Outperform
Price Target: $300 → $360
Current: $321.32
Upside: +12.04%
Sarepta Therapeutics
Jun 16, 2025
Downgrades: Market Perform
Price Target: $120 → $70
Current: $17.38
Upside: +302.76%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $2.57
Upside: +211.28%
Avidity Biosciences
Mar 12, 2025
Initiates: Outperform
Price Target: $72
Current: $29.68
Upside: +142.59%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $9.88
Upside: +406.07%
Silence Therapeutics
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $5.91
Upside: +323.01%
Ionis Pharmaceuticals
Feb 20, 2025
Maintains: Market Perform
Price Target: $60 → $45
Current: $39.80
Upside: +13.07%
Intellia Therapeutics
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $9.75
Upside: +412.82%
Precision BioSciences
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $4.35
Upside: +681.61%
Centessa Pharmaceuticals
Sep 16, 2024
Maintains: Outperform
Price Target: $20 → $35
Current: $12.97
Upside: +169.85%
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.59
Upside: +969.18%
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $4.03
Upside: +892.56%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $35.80
Upside: +151.40%
May 15, 2024
Maintains: Outperform
Price Target: $120
Current: $12.21
Upside: +882.80%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $17.21
Upside: +231.20%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $44.99
Upside: -17.76%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $54.95
Upside: +81.98%
Oct 9, 2023
Initiates: Outperform
Price Target: $19
Current: $2.51
Upside: +656.97%
Jul 18, 2022
Maintains: Outperform
Price Target: $48 → $62
Current: $11.29
Upside: +449.40%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $47.47
Upside: +106.45%